Description

Tivozanib 0.89mg Capsules

Tivozanib 0.89mg Capsules represent a specialized strength of a potent, selective, and long-acting tyrosine kinase inhibitor (TKI) designed to combat advanced kidney cancer. Pharmacologically, the medication functions as a highly selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).

In Renal Cell Carcinoma (RCC), tumor cells produce high levels of VEGF to stimulate the growth of new blood vessels (angiogenesis), which provide the cancer with oxygen and nutrients essential for survival and proliferation. Tivozanib 0.89mg Capsules work by binding to the intracellular kinase domain of the VEGF receptors, effectively shutting down this signaling pathway. Unlike some multi-kinase inhibitors that hit a wide range of targets (often leading to “off-target” side effects), tivozanib’s high selectivity for VEGFR aims to maximize the blockade of angiogenesis while minimizing toxicity. This strength is primarily utilized for dose management in patients who require a reduction from the standard starting dose due to tolerability issues.

Indications / Uses of Tivozanib 0.89mg Capsules

Tivozanib 0.89mg Capsules are indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The specific utility of this lower strength includes:

• Dose Reduction: The 0.89mg capsule is the designated strength for patients who experience Grade 3 or persistent Grade 2 adverse reactions (such as severe hypertension or fatigue) while on the standard 1.34mg dose. It allows for continued therapy at a manageable exposure level.
• Refractory Disease: Indicated for patients who have received two or more prior systemic therapies, offering a line of defense when other standard treatments (like immunotherapy or other TKIs) have failed.
• Angiogenesis Suppression: Used to inhibit the formation of new blood vessels within the tumor, thereby starving the cancer cells and slowing disease progression.

Key Features

• High Selectivity: Its molecular design focuses intensely on the VEGFR family, which contributes to a favorable efficacy-to-toxicity profile compared to less selective agents.
• Long Half-Life: Tivozanib has an exceptionally long half-life (approximately 4 days), which ensures sustained inhibition of the target receptors with once-daily dosing.
• Cyclic Dosing Regimen: The treatment is administered in cycles: 21 days of daily medication followed by 7 days off. This “3 weeks on, 1 week off” schedule allows the patient’s body to recover from toxicity while maintaining therapeutic pressure on the tumor.
• Oral Administration: Formulated as a capsule, it provides a convenient, home-based oral therapy option.

Storage for Tivozanib 0.89mg Capsules

To ensure the stability and safety of Tivozanib 0.89mg Capsules, proper storage is essential. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the capsules in their original container to protect them from moisture and light. Do not store the medication in humid environments like bathrooms. Ensure the bottle is tightly closed after every use and kept securely out of the reach and sight of children and pets.

Important Note on Tivozanib 0.89mg Capsules

Treatment with Tivozanib 0.89mg Capsules requires careful monitoring, particularly for hypertension (high blood pressure). This is a known class effect of potent VEGF inhibitors. Blood pressure should be well-controlled before starting treatment and monitored actively during therapy; antihypertensive therapy may be required.

Other potential serious side effects include cardiac failure, arterial thromboembolic events (such as heart attack or stroke), and venous thromboembolism (blood clots). Proteinuria (protein in the urine) and thyroid dysfunction can also occur, necessitating regular urine and blood tests.

Tivozanib can cause fetal harm and is not recommended for pregnant women. Females of reproductive potential and males with female partners should use effective contraception during treatment and for one month after the final dose.

The medication should be taken with or without food. If a dose is missed, the next dose should be taken at the regularly scheduled time; do not take an extra dose to make up for the missed one. Always adhere to the specific “on-off” cycle prescribed by your oncologist.